Joining the ‘Most Innovative Square Mile’ 

Bristol-Myers Squibb Opens Newest Labs in Kendall Square R&D hub

November 26, 2018

S

itting in the heart of Cambridge’s vibrant innovation ecosystem, Bristol-Myers Squibb’s new Kendall Square research facility is home to a fully integrated drug discovery and translational medicine organization.

Cambridge, MA - Bristol-Myers Squibb's New lab

Bristol-Myers Squibb’s new Kendall Square research in Cambridge, MA

Since leading the development of the first immuno-oncology treatments, our scientists continue to ask – “why don’t some cancers respond to immuno-oncology therapy?” In Kendall Square, often called the “Most Innovative Square Mile,’ answering that question will be a central focus.

The state-of-the-art laboratories, the team of leading researchers and the close proximity to academic and industry partners, positions BMS to deliver on a vision of transforming outcomes for patients. 

The teams there will head the most nascent stages of drug discovery, through molecular discovery technologies and discovery platform chemistry.

These efforts are laying the foundation for investigational molecules that may one day have a therapeutic impact on our disease areas of focus.

Our scientists have access to the latest tools, equipment and resources of a large pharmaceutical company, within the progressive environment of a biotech company, providing the flexibility and freedom to follow emerging areas of research. The dynamic Cambridge landscape will only add to our ability to push the boundaries of medicine and disrupt the standards of care in areas of high, unmet need. 

Related Content

Leading the Charge Against I-O Resistance

Mike Quigley, executive director and co-lead of Bristol-Myers Squibb’s I-O resistance biology team, walks through the discovery process in our state-of-the-art lab space.

Leveraging Bioinformatics: Joe Szustakowski

Hear from Joe Szustakowski, head of translational bioinformatics, about how his team uses raw data and distills that into a useful biological signals.

Exploring Pathology: Mike Montalto

Hear from Mike Montalto, vice president of pathology & clinical biomarker laboratories, about how translational pathology, immunohistochemistry, clinical genomics and genetics, and clinical flow cytometry are being used in cancer research.

Building Toward a Translational Future

Building Toward a Translational Future

Saurabh Saha leads the translational medicine team and returns to the Boston-area to build out the new R&D facility in Cambridge.

Sharon Cload, Vice President

The Scientists Behind the Science

Sharon Cload, vice president of Molecular Discovery Technology, is one of many researchers at a new Cambridge, Mass., lab space.

Tom Lynch on New Collaborations

The New Collaboration Ecosystem

Drug development is at its very core a collaborative process.